Nirsevimab Slashing Pediatric LRTI Hospitalizations by Over 60%: Real-World Evidence Supports Universal Immunization
Posted inInfectious Diseases news Pediatrics

Nirsevimab Slashing Pediatric LRTI Hospitalizations by Over 60%: Real-World Evidence Supports Universal Immunization

A comprehensive meta-analysis of over 260,000 infants confirms that nirsevimab significantly reduces respiratory syncytial virus (RSV) and lower respiratory tract infection (LRTI) hospitalizations and emergency department visits, providing a robust evidence base for pediatric immunization strategies.
Nirsevimab in Chile’s First National RSV Campaign: 76% Reduction in RSV Hospitalisations and 85% Fewer ICU Admissions in Infants
Posted inInfectious Diseases news Pediatrics Public Health Respiratory

Nirsevimab in Chile’s First National RSV Campaign: 76% Reduction in RSV Hospitalisations and 85% Fewer ICU Admissions in Infants

A nationwide retrospective study from Chile finds that a universal nirsevimab immunisation strategy in 2024 reduced RSV-related lower respiratory tract infection hospitalisations by 76% and ICU admissions by 85%, with an NNT of 35 to prevent one RSV LRTI admission.
Real-world data suggest nirsevimab reduces RSV test-positivity up to 12 months but not beyond — cautious interpretation required
Posted inInfectious Diseases news Pediatrics Respiratory

Real-world data suggest nirsevimab reduces RSV test-positivity up to 12 months but not beyond — cautious interpretation required

A multicentre retrospective TriNetX analysis found reduced odds of RSV test-positivity for infants receiving nirsevimab when last dose was within 6–11 months before testing; protection was strongest within 6 months and not evident beyond 12 months. Methodological limits temper causal inference.